HUTCHMED announces contract renewal with China NHSA, including ELUNATE®, ORPATHYS®, SULANDA®, and TAZVERIK® on updated NRDL effective Jan 1, 2026. ELUNATE® for endometrial and colorectal cancer, ORPATHYS® for NSCLC, SULANDA® for neuroendocrine tumors, and TAZVERIK® for follicular lymphoma. NHSA established Commercial Insurance Drug List for innovative, high-cost medicines beyond basic insurance. NRDL updated annually to improve drug affordability for Chinese population. Fruquintinib, savolitinib, surufatinib, and tazemetostat details provided. HUTCHMED focused on global development of targeted therapies for cancer and immunological diseases.

Read more at GlobeNewswire: HUTCHMED Announces Expanded Coverage on National